Management of Deep Infiltrating Endometriosis in Premenopausal Women with Chronic Pelvic Pain

Disease Definition and Pathophysiology

Deep infiltrating endometriosis (DIE) is defined as endometriotic lesions extending >5 mm beneath the peritoneal surface or involving the bowel, bladder, ureter, or vagina. 3
Endometriosis is a chronic estrogen‑dependent inflammatory disease that commonly causes pelvic pain and infertility. 3
Endometriotic implants exhibit estrogen dependence and resistance to progesterone, underpinning the rationale for hormonal suppression. 3

Transvaginal ultrasound performed with an expanded protocol (including assessment of uterosacral ligaments, anterior rectosigmoid wall, dynamic sliding maneuvers, bowel preparation, and evaluation of appendix and diaphragm) is the recommended first‑line imaging modality, achieving a sensitivity of approximately 82 % and specificity of 85 % for DIE. 2
If the expanded transvaginal ultrasound is inconclusive, pelvic magnetic resonance imaging (MRI) without intravenous contrast should be obtained; MRI demonstrates a sensitivity of ≈ 90 % and specificity of ≈ 91 % for deep pelvic endometriosis. 2
MRI diagnostic performance by lesion location: intestinal DIE – sensitivity ≈ 92 % and specificity ≈ 95 %; deep infiltrating lesions of other sites – sensitivity ≈ 88 % and specificity ≈ 83 %. 5
A normal imaging study does not exclude endometriosis, especially superficial peritoneal disease that is poorly detected by current imaging techniques. 2

Continuous combined oral contraceptives (COCs) or progestin‑only regimens (e.g., dienogest, norethisterone acetate, medroxyprogesterone acetate) may be initiated empirically without prior surgical confirmation, providing significant pain relief with a favorable safety and cost profile. 1
Continuous COCs are as effective as GnRH agonists for pain control but are associated with markedly fewer adverse effects. 1
Progestin‑only therapy shows comparable efficacy to COCs in reducing pain intensity and lesion size. 1

GnRH agonists should be used for a minimum of 3 months, combined with mandatory add‑back therapy (low‑dose estrogen and/or progestin) to preserve bone mineral density without compromising analgesic benefit. 1
Danazol administered for at least 6 months provides pain relief equivalent to GnRH agonists and is supported by Level A evidence. 1

Surgery is indicated when medical therapy is ineffective, contraindicated, or when disease severity warrants operative management. 1
Excisional surgery performed by an experienced endometriosis specialist is considered definitive; medical therapy temporizes symptoms but does not eradicate disease. 1
Recurrence of symptoms occurs in up to 44 % of women within 12 months after surgical excision of DIE. 1
Hysterectomy with bilateral salpingo‑oophorectomy remains a definitive option for women who have completed childbearing, yet approximately 25 % experience recurrent pelvic pain and 10 % require additional surgery. 1

Estrogen‑based hormone replacement therapy is not contraindicated after hysterectomy with bilateral oophorectomy for endometriosis. 1
If hysterectomy is performed without oophorectomy, continued medical suppression may be necessary because residual ovarian estrogen production can stimulate any remaining endometriotic tissue. 1

No medical therapy completely eliminates endometriotic lesions; 11–19 % of patients do not achieve meaningful pain reduction with hormonal agents, and 25–34 % experience recurrent pelvic pain within 12 months after discontinuation of therapy. 1
Hormonal suppression does not improve future fertility outcomes and should be avoided in women actively seeking pregnancy. 1
Pre‑operative imaging that accurately delineates DIE reduces operative morbidity by guiding the need for intestinal or urologic surgical expertise. 5